Computational Analysis of a Wearable Artificial Pump Lung Device in Terms of Rotor/Stator Interactions

Lung Disease ◽

Computational Analysis ◽

Respiratory Support ◽

Membrane Oxygenation ◽

Current Therapies

Lung disease is America’s third largest killer, and responsible for one in seven deaths [1]. Most lung disease is chronic, and respiratory support is essential. Current therapies for the respiratory failure include mechanical ventilation and bed-side extracorporeal membrane oxygenation (ECMO) devices which closely simulate the physiological gas exchange of the natural lung.

Physiology of Gas Exchange During ECMO for Respiratory Failure

Journal of Intensive Care Medicine ◽

10.1177/0885066616641383 ◽

2016 ◽

Vol 32 (4) ◽

pp. 243-248 ◽

Cited By ~ 17

Author(s):

Robert H. Bartlett

Keyword(s):

Mechanical Ventilation ◽

Respiratory Failure ◽

Gas Exchange ◽

Venous Blood ◽

Arterial Oxygenation ◽

Membrane Lung ◽

Management of gas exchange using extracorporeal membrane oxygenation (ECMO) in respiratory failure is very different than management when the patient is dependent on mechanical ventilation. All the gas exchange occurs in the membrane lung, and the arterial oxygenation is the result of mixing the ECMO blood with the native venous blood. To manage patients on ECMO, it is essential to understand the physiology described in this essay.

Chronic respiratory disease and survival outcomes after extracorporeal membrane oxygenation

Respiratory Research ◽

10.1186/s12931-021-01796-8 ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Tak Kyu Oh ◽

Hyoung-Won Cho ◽

Hun-Taek Lee ◽

In-Ae Song

Keyword(s):

Respiratory Failure ◽

Lung Disease ◽

Respiratory Disease ◽

Chronic Respiratory Disease ◽

Newly Diagnosed ◽

Membrane Oxygenation ◽

Obstructive Sleep ◽

All Cause Mortality ◽

Ecmo Therapy

Abstract Background Quality of life following extracorporeal membrane oxygenation (ECMO) therapy is an important health issue. We aimed to describe the characteristics of patients who developed chronic respiratory disease (CRD) following ECMO therapy, and investigate the association between newly diagnosed post-ECMO CRDs and 5-year all-cause mortality among ECMO survivors. Methods We analyzed data from the National Health Insurance Service in South Korea. All adult patients who underwent ECMO therapy in the intensive care unit between 2006 and 2014 were included. ECMO survivors were defined as those who survived for 365 days after ECMO therapy. Chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, lung cancer, lung disease due to external agents, obstructive sleep apnea, and lung tuberculosis were considered as CRDs. Results A total of 3055 ECMO survivors were included, and 345 (11.3%) were newly diagnosed with CRDs 365 days after ECMO therapy. The prevalence of asthma was the highest at 6.1% (185). In the multivariate logistic regression, ECMO survivors who underwent ECMO therapy for acute respiratory distress syndrome (ARDS) or respiratory failure had a 2.00-fold increase in post-ECMO CRD (95% confidence interval [CI]: 1.39 to 2.89; P < 0.001). In the multivariate Cox regression, newly diagnosed post-ECMO CRD was associated with a 1.47-fold (95% CI: 1.17 to 1.86; P = 0.001) higher 5-year all-cause mortality. Conclusions At 12 months after ECMO therapy, 11.3% of ECMO survivors were newly diagnosed with CRDs. Patients who underwent ECMO therapy for ARDS or respiratory failure were associated with a higher incidence of newly diagnosed post-ECMO CRD compared to those who underwent ECMO for other causes. Additionally, post-ECMO CRDs were associated with a higher 5-year all-cause mortality. Our results suggest that ECMO survivors with newly diagnosed post-ECMO CRD might be a high-risk group requiring dedicated interventions.

Mechanical ventilation and respiratory monitoring during extracorporeal membrane oxygenation for respiratory support

Annals of Translational Medicine ◽

10.21037/atm.2018.10.11 ◽

2018 ◽

Vol 6 (19) ◽

pp. 386-386 ◽

Cited By ~ 6

Author(s):

Nicolò Patroniti ◽

Giulia Bonatti ◽

Tarek Senussi ◽

Chiara Robba

Keyword(s):

Mechanical Ventilation ◽

Respiratory Monitoring ◽

Respiratory Support ◽

Frequency of chronic lung disease in infants with severe respiratory failure treated with high-frequency ventilation and/or extracorporeal membrane oxygenation

Critical Care Medicine ◽

10.1097/00003246-199203000-00014 ◽

1992 ◽

Vol 20 (3) ◽

pp. 372-377 ◽

Cited By ~ 20

Author(s):

CLAIR A. SCHWENDEMAN ◽

REESE H. CLARK ◽

BRADLEY A. YODER ◽

DONALD M. NULL ◽

DALE R. GERSTMANN ◽

...

Keyword(s):

Respiratory Failure ◽

Lung Disease ◽

Chronic Lung Disease ◽

High Frequency ◽

High Frequency Ventilation ◽

Severe Respiratory Failure ◽

Membrane Oxygenation ◽

Frequency Ventilation

Clinical outcomes of patients receiving prolonged extracorporeal membrane oxygenation for respiratory support

Therapeutic Advances in Respiratory Disease ◽

10.1177/1753466619848941 ◽

2019 ◽

Vol 13 ◽

pp. 175346661984894 ◽

Cited By ~ 4

Author(s):

Soo Jin Na ◽

Jae-Seung Jung ◽

Sang-Bum Hong ◽

Woo Hyun Cho ◽

Sang-Min Lee ◽

...

Keyword(s):

Respiratory Failure ◽

Mortality Rate ◽

Hospital Mortality ◽

Acute Respiratory Failure ◽

Ecmo Support ◽

Respiratory Support ◽

Short Term ◽

Background: There are limited data regarding prolonged extracorporeal membrane oxygenation (ECMO) support, despite increase in ECMO use and duration in patients with respiratory failure. The objective of this study was to investigate the outcomes of severe acute respiratory failure patients supported with prolonged ECMO for more than 28 days. Methods: Between January 2012 and December 2015, all consecutive adult patients with severe acute respiratory failure who underwent ECMO for respiratory support at 16 tertiary or university-affiliated hospitals in South Korea were enrolled retrospectively. The patients were divided into two groups: short-term group defined as ECMO for ⩽28 days and long-term group defined as ECMO for more than 28 days. In-hospital and 6-month mortalities were compared between the two groups. Results: A total of 487 patients received ECMO support for acute respiratory failure during the study period, and the median support duration was 8 days (4–20 days). Of these patients, 411 (84.4%) received ECMO support for ⩽28 days (short-term group), and 76 (15.6%) received support for more than 28 days (long-term group). The proportion of acute exacerbation of interstitial lung disease as a cause of respiratory failure was higher in the long-term group than in the short-term group (22.4% versus 7.5%, p < 0.001), and the duration of mechanical ventilation before ECMO was longer (4 days versus 1 day, p < 0.001). The hospital mortality rate (60.8% versus 69.7%, p = 0.141) and the 6-month mortality rate (66.2% versus 74.0%, p = 0.196) were not different between the two groups. ECMO support longer than 28 days was not associated with hospital mortality in univariable and multivariable analyses. Conclusions: Short- and long-term survival rates among patients receiving ECMO support for more than 28 days for severe acute respiratory failure were not worse than those among patients receiving ECMO for 28 days or less.

S9 Acute Inflammatory Presentation Associates With Survival In Interstitial Lung Disease And Extracorporeal Membrane Oxygenation-requiring Severe Respiratory Failure: A Single Centre Case Series

Thorax ◽

10.1136/thoraxjnl-2014-206260.15 ◽

2014 ◽

Vol 69 (Suppl 2) ◽

pp. A7-A8 ◽

Cited By ~ 2

Author(s):

L. Starsmore ◽

B. Lams ◽

S. Agarwal ◽

A. Nair ◽

R. Preston ◽

...

Keyword(s):

Respiratory Failure ◽

Interstitial Lung Disease ◽

Lung Disease ◽

Case Series ◽

Severe Respiratory Failure ◽

Single Centre ◽

Efficacy of extracorporeal membrane oxygenation for acute respiratory failure with interstitial lung disease: a case control nationwide dataset study in Japan

Respiratory Research ◽

10.1186/s12931-021-01805-w ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Yuko Usagawa ◽

Kosaku Komiya ◽

Mari Yamasue ◽

Kiyohide Fushimi ◽

Kazufumi Hiramatsu ◽

...

Keyword(s):

Prognostic Factors ◽

Respiratory Failure ◽

Interstitial Lung Disease ◽

Hospital Mortality ◽

Acute Respiratory Failure ◽

Lung Disease ◽

Case Control ◽

Antifungal Drugs ◽

Abstract Background Whether acute respiratory failure in patients with interstitial lung disease is reversible remains uncertain. Consequently, indications for extracorporeal membrane oxygenation in these patients are still controversial, except as a bridge to lung transplantation. The objective of this study was to clarify in-hospital mortality and prognostic factors in interstitial lung disease patients undergoing extracorporeal membrane oxygenation. Methods In this case–control study using the Japanese Diagnosis Procedure Combination database, hospitalized interstitial lung disease patients receiving invasive mechanical ventilation and extracorporeal membrane oxygenation from 2010 to 2017 were reviewed. Patients’ characteristics and treatment regimens were compared between survivors and non-survivors to identify prognostic factors. To avoid selection biases, patients treated with extracorporeal membrane oxygenation as a bridge to lung transplantation were excluded. Results A total of 164 interstitial lung disease patients receiving extracorporeal membrane oxygenation were included. Their in-hospital mortality was 74.4% (122/164). Compared with survivors, non-survivors were older and received high-dose cyclophosphamide, protease inhibitors, and antifungal drugs more frequently, but macrolides and anti-influenza drugs less frequently. On multivariate analysis, the following factors were associated with in-hospital mortality: advanced age (odds ratio [OR] 1.043; 95% confidence interval [CI] 1.009–1.078), non-use of macrolides (OR 0.305; 95% CI 0.134–0.698), and use of antifungal drugs (OR 2.416; 95% CI 1.025–5.696). Conclusions Approximately three-quarters of interstitial lung disease patients undergoing extracorporeal membrane oxygenation died in hospital. Moreover, advanced age, non-use of macrolides, and use of antifungal drugs were found to correlate with a poor prognosis.

Efficacy of extracorporeal membrane oxygenation for acute respiratory failure with interstitial lung disease; a case control nationwide dataset study in Japan

10.21203/rs.3.rs-152666/v2 ◽

2021 ◽

Author(s):

Yuko Usagawa ◽

Kosaku Komiya ◽

Mari Yamasue ◽

Kiyohide Fushimi ◽

Kazufumi Hiramatsu ◽

...

Keyword(s):

Respiratory Failure ◽

Interstitial Lung Disease ◽

Hospital Mortality ◽

Acute Respiratory Failure ◽

Lung Transplantation ◽

Lung Disease ◽

Case Control ◽

Antifungal Drugs ◽

Abstract Background: Since it is uncertain whether acute respiratory failure in patients with interstitial lung disease is reversible, indications for extracorporeal membrane oxygenation in these patients remain controversial, except for bridging to lung transplantation. The objective of this study was to clarify in-hospital mortality and prognostic factors in interstitial lung disease patients undergoing extracorporeal membrane oxygenation.Methods: Case-control study. Using the Japanese Diagnosis Procedure Combination database from 2010 to 2017, we reviewed hospitalized interstitial lung disease patients receiving invasive mechanical ventilation and extracorporeal membrane oxygenation. As we focused on the efficacy of extracorporeal membrane oxygenation as an intervention for managing merely acute respiratory failure, patients treated with extracorporeal membrane oxygenation as a bridge to lung transplantation were excluded.Results: A total of 164 interstitial lung disease patients receiving extracorporeal membrane oxygenation were included. In-hospital mortality of them was 74.4% (122/164). Compared with survivors, non-survivors were older and received high-dose cyclophosphamide, protease inhibitors, and antifungal drugs more frequently but macrolides and anti-influenza drugs less frequently. Multivariate analysis revealed the following factors were associated with in-hospital mortality: advanced age with an odds ratio (OR) of 1.048 and a 95% confidence interval (CI) of 1.015–1.082, non-use of macrolides (OR, 0.264; 95% CI, 0.118–0.589), and use of antifungal drugs (OR, 3.158; 95% CI, 1.377–7.242).Conclusions: Approximately three quarters of interstitial lung disease patients undergoing extracorporeal membrane oxygenation died in hospital. Moreover, advanced age, non-use of macrolides, and use of antifungal drugs were found to correlate with a poor prognosis.